New insights obtained using cell binding measurements may improve how cell therapies are designed

By Jane Byrne contact

- Last updated on GMT

© GettyImages/Design Cells
© GettyImages/Design Cells

Related tags: CAR T cell therapy, binding, solid tumor

A study that reveals new understanding of Chimeric Antigen Receptor (CAR) T cell functionality is said to underscore the critical role that cell avidity or binding plays in uncovering and optimizing CAR T cells.

The research was led by Dr John Maher, senior lecturer in the School of Cancer & Pharmaceutical Sciences, Kings College London, and CSO at Leucid Bio, in collaboration with biotech company, Lumicks; it was published in the February 2022 issue of Frontiers in Immunology.

The paper describes a new Chimeric Antigen Receptor (CAR) T-cell therapy that adds a second receptor, enhancing the ability of the CAR T-cell to target and destroy specific cancer cells in pre-clinical models. The genetic edits provide new promise in improving its effectiveness as an immunotherapy for cancer, said the authors.

Testing binding strength 

Dr Maher and his colleagues were able to utilize the z-Movi Cell Avidity Analyzer as part of their collaboration with Lumicks. The analyzer measures avidity: the strength of binding between the antibody and the antigen on its target. The authors used the technology to measure the strength of binding between the CAR T-cell and the target cancer cells.

Using that analytical instrument, Dr Maher said the researchers could easily find the ‘goldilocks’ CARs that do not bind too strongly or too weakly to the target cells and show superior killing in pre-clinical models. “New insights obtained using cell avidity measurements can really help improve the way we design cell therapies,”​ he added.

First introduced in 2020, the z-Movi has been used in both academic and biopharma laboratories globally, according to Lumicks. Andrea Candelli, CSO at that Dutch life sciences company, said the study provides “additional evidence of the critical role that measuring cell avidity plays in uncovering and optimizing CAR T cells in making immunotherapy more effective.”

Dr Maher’s group is hoping to design CAR T-cell therapy for solid tumors. CAR T-cells are currently offered as treatments for blood cancers on the NHS.

Related news

Show more

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers

Follow us

Products

View more

Webinars